Mechanisms of IVIG Efficacy in Chronic Inflammatory Demyelinating Polyneuropathy

[1] Koller H(2005)Chronic inflammatory demyelinating polyneuropathy N Engl J Med 352 1343-56

[2] Kieseier BC(2009)Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population Muscle Nerve 39 432-8

[3] Jander S(2009)Incidence and prevalence of CIDP and the association of diabetes mellitus Neurology 73 39-45

[4] Hartung HP(1975)Chronic inflammatory polyradiculoneuropathy Mayo Clin Proc 50 621-37

[5] Rajabally YA(2001)Clinical spectrum of chronic acquired demyelinating polyneuropathies Muscle Nerve 24 311-24

[6] Simpson BS(2007)From bench to bedside—experimental rationale for immune-specific therapies in the inflamed peripheral nerve Nat Clin Pract Neurol 3 198-211

[7] Beri S(2002)Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10 Brain 125 823-34

[8] Bankart J(2000)Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients Ann Neurol 47 765-75

[9] Gosalakkal JA(2002)Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies Neurology 59 S13-21

[10] Laughlin RS(2008)Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial Lancet Neurol 7 136-44

[1] Koller H(2005)Chronic inflammatory demyelinating polyneuropathy N Engl J Med 352 1343-56

[2] Kieseier BC(2009)Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population Muscle Nerve 39 432-8

[3] Jander S(2009)Incidence and prevalence of CIDP and the association of diabetes mellitus Neurology 73 39-45

[4] Hartung HP(1975)Chronic inflammatory polyradiculoneuropathy Mayo Clin Proc 50 621-37

[5] Rajabally YA(2001)Clinical spectrum of chronic acquired demyelinating polyneuropathies Muscle Nerve 24 311-24

[6] Simpson BS(2007)From bench to bedside—experimental rationale for immune-specific therapies in the inflamed peripheral nerve Nat Clin Pract Neurol 3 198-211

[7] Beri S(2002)Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10 Brain 125 823-34

[8] Bankart J(2000)Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients Ann Neurol 47 765-75

[9] Gosalakkal JA(2002)Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies Neurology 59 S13-21

[10] Laughlin RS(2008)Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial Lancet Neurol 7 136-44